Capnography During Percutaneous Transhepatic Cholangiodrainage (PTCD) (HepaBreath)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01587157

Enrollment

Registered

2012-04-30

Start date

2010-08-31

Completion date

2011-08-31

Last updated

2012-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apnea, Complications, Hypoxemia

Brief summary

Capnography provides noninvasive monitoring of ventilation and can allow early recognition of altered respiration patterns and apnea. The aim of this prospective study was to compare the detection of apnea and the prediction of oxygen desaturation and hypoxemia by capnography versus clinical surveillance during procedural sedation for percutaneous transhepatic cholangiodrainage (PTCD).

Interventions

PROCEDUREcapnography

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age\>=18 * Scheduled for PTCD with midazolam and propofol sedation

Exclusion criteria

* age less than 18 years * ASA class V * allergy to narcotic drugs * pregnancy * pre-existing hypotension, bradycardia or hypoxemia

Design outcomes

Primary

Measure	Time frame
mean cumulative duration of detected apnea episodes per patient (capnographic vs. clinical surveillance)	—

Secondary

Measure	Time frame
overall number of detected episodes of apnea	—
the occurrences of oxygen desaturation and hypoxemia	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026